Business Context and Reporting Period
This Form 8-K is filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on July 24, 2019. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Stamford, Connecticut. The filing primarily addresses the commencement of a public offering of common stock and provides updated liquidity information as of June 30, 2019.
Key Financial Metrics
- Liquidity: As of June 30, 2019, the company reported approximately $135.6 million in cash, cash equivalents, and marketable securities.
- Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period.
- Debt: The filing text does not provide specific values for outstanding debt.
Material Changes and Events
- Public Offering: On July 24, 2019, the company commenced a public offering of its common stock.
- Prospectus Supplement: The company filed a preliminary prospectus supplement with the SEC disclosing the liquidity position mentioned above.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a detailed discussion of risks beyond the standard legal disclaimers. The information provided in Item 2.02 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the final terms and proceeds of the public offering of common stock announced on July 24, 2019.
- Confirm the updated cash position post-offering by reviewing the final prospectus supplement.
- Review the full press release (Exhibit 99.1) for details on the use of proceeds from the offering.
- Note that the company name in the metadata request ("Tvardi") differs from the registrant in the filing ("Cara Therapeutics").